Search

Author/Creator Walling, David P

1. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. (March 2021)

Authors:
Fleischhacker, W Wolfgang; Podhorna, Jana; Gröschl, Martina; Hake, Sanjay; Zhao, Yihua; Huang, Songqiao; Keefe, Richard S E; Desch, Michael; Brenner, Ronald; Walling, David P; Mantero-Atienza, Emilio; Nakagome, Kazuyuki; Pollentier, Stephane
Journal:
Lancet
Issue:
Volume 8:Number 3(2021)
Page Start:
191
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Issue 10369 (17th December 2022)

Authors:
Krystal, John H; Kane, John M; Correll, Christoph U; Walling, David P; Leoni, Matthew; Duvvuri, Sridhar; Patel, Shrinal; Chang, Ih; Iredale, Philip; Frohlich, Lillian; Versavel, Stacey; Perry, Pamela; Sanchez, Raymond; Renger, John
Journal:
Lancet
Issue:
Volume 400:Issue 10369(2022)
Page Start:
2210
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search